{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T16:22:42Z","timestamp":1785428562792,"version":"3.56.0"},"reference-count":54,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2024,7,1]]},"abstract":"<jats:sec id=\"ab-eoi240030-4\"><jats:title>Importance<\/jats:title><jats:p>Melatonin has been shown to oppose several processes that are known to mediate age-related macular degeneration (AMD), but whether melatonin can confer benefits against AMD remains unclear.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi240030-5\"><jats:title>Objective<\/jats:title><jats:p>To examine the association between melatonin supplementation and the risk of the development or progression of AMD.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi240030-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This retrospective cohort study accessed data from TriNetX, a national database of deidentified electronic medical records from both inpatient and outpatient health care organizations across the US, between December 4, 2023, and March 19, 2024. Patients aged 50 years or older, 60 years or older, and 70 years or older with no history of AMD (AMD-naive group) and with a history of nonexudative AMD (nonexudative AMD group) were queried for instances of melatonin medication codes between November 14, 2008, and November 14, 2023. Patients were then classified into either a melatonin group or a control group based on the presence of medication codes for melatonin. Propensity score matching (PSM) was performed to match the cohorts based on demographic variables, comorbidities, and nonmelatonin hypnotic medication use.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi240030-7\"><jats:title>Exposure<\/jats:title><jats:p>The presence of at least 4 instances of melatonin records that each occurred at least 3 months apart.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi240030-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>After PSM, the melatonin and the control cohorts were compared to evaluate the risk ratios (RRs) and the 95% CIs of having an outcome. For the AMD-naive group, the outcome was defined as a new diagnosis of any AMD, whereas for the nonexudative AMD group, the outcome was progression to exudative AMD.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi240030-9\"><jats:title>Results<\/jats:title><jats:p>Among 121\u202f523 patients in the melatonin-naive group aged 50 years or older (4848 in the melatonin cohort [4580 after PSM; mean (SD) age, 68.24 (11.47) years; 2588 female (56.5%)] and 116\u202f675 in the control cohort [4580 after PSM; mean (SD) age, 68.17 (10.63) years; 2681 female (58.5%)]), melatonin use was associated with a reduced risk of developing AMD (RR, 0.42; 95% CI, 0.28-0.62). Among 66\u202f253 patients aged 50 years or older in the nonexudative AMD group (4350 in the melatonin cohort [4064 after PSM; mean (SD) age, 80.21 (8.78) years; 2482 female (61.1%)] and 61\u202f903 in the control cohort [4064 patients after PSM; mean (SD) age, 80.31 (8.03) years; 2531 female (62.3%)]), melatonin was associated with a reduced risk of AMD progression to exudative AMD (RR, 0.44; 95% CI, 0.34-0.56). The results were consistent among subsets of individuals aged 60 years or older (AMD-naive cohort: RR, 0.36 [95% CI, 0.25-0.54]; nonexudative AMD cohort: RR, 0.38 [95% CI, 0.30-0.49]) and 70 years or older (AMD-naive cohort: RR, 0.35 [95% CI, 0.23-0.53]; nonexudative AMD cohort: RR, 0.40 [95% CI, 0.31-0.51]).<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi240030-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>Melatonin use was associated with a decreased risk of development and progression of AMD. Although lifestyle factors may have influenced this association, these findings provide a rationale for further research on the efficacy of using melatonin as a preventive therapy against AMD.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2024.1822","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T15:33:03Z","timestamp":1717687983000},"page":"648","source":"Crossref","is-referenced-by-count":24,"title":["Melatonin and Risk of Age-Related Macular Degeneration"],"prefix":"10.1001","volume":"142","author":[{"given":"Hejin","family":"Jeong","sequence":"first","affiliation":[{"name":"Case Western Reserve University School of Medicine, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline K.","family":"Shaia","sequence":"additional","affiliation":[{"name":"Case Western Reserve University School of Medicine, Cleveland, Ohio"},{"name":"Center for Ophthalmic Bioinformatics, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C.","family":"Markle","sequence":"additional","affiliation":[{"name":"Center for Ophthalmic Bioinformatics, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine E.","family":"Talcott","sequence":"additional","affiliation":[{"name":"Center for Ophthalmic Bioinformatics, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi P.","family":"Singh","sequence":"additional","affiliation":[{"name":"Center for Ophthalmic Bioinformatics, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio"},{"name":"Cleveland Clinic Martin Health, Cleveland Clinic Florida, Stuart"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"12","key":"eoi240030r2","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1001\/archopht.124.12.1754","article-title":"The economic burden of major adult visual disorders in the United States.","volume":"124","author":"Rein","year":"2006","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"eoi240030r3","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1136\/bjo.87.3.312","article-title":"How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom?","volume":"87","author":"Owen","year":"2003","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"eoi240030r4","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.mehy.2010.08.036","article-title":"Potential of melatonin to treat or prevent age-related macular degeneration through stimulation of telomerase activity.","volume":"76","author":"Rastmanesh","year":"2011","journal-title":"Med Hypotheses"},{"issue":"8","key":"eoi240030r5","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1111\/ceo.v48.8","article-title":"Retinal pigment epithelium and age-related macular degeneration: a review of major disease mechanisms.","volume":"48","author":"Somasundaran","year":"2020","journal-title":"Clin Exp Ophthalmol"},{"issue":"1","key":"eoi240030r6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.neuron.2012.06.018","article-title":"Mechanisms of age-related macular degeneration.","volume":"75","author":"Ambati","year":"2012","journal-title":"Neuron"},{"issue":"6","key":"eoi240030r7","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s40259-021-00499-2","article-title":"Anti-VEGF and other novel therapies for neovascular age-related macular degeneration: an update.","volume":"35","author":"Parravano","year":"2021","journal-title":"BioDrugs"},{"issue":"29-30","key":"eoi240030r8","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3238\/arztebl.2020.0513","article-title":"The diagnosis and treatment of age-related macular degeneration.","volume":"117","author":"Stahl","year":"2020","journal-title":"Dtsch Arztebl Int"},{"issue":"15","key":"eoi240030r11","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.3390\/jcm10153297","article-title":"Prevention of the onset of age-related macular degeneration.","volume":"10","author":"Di Carlo","year":"2021","journal-title":"J Clin Med"},{"issue":"1","key":"eoi240030r12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.31887\/DCNS.2002.4.1\/ppevet","article-title":"Melatonin.","volume":"4","author":"P\u00e9vet","year":"2002","journal-title":"Dialogues Clin Neurosci"},{"issue":"6","key":"eoi240030r13","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1080\/01616412.2017.1315864","article-title":"A review of sleep disorders and melatonin.","volume":"39","author":"Xie","year":"2017","journal-title":"Neurol Res"},{"issue":"3","key":"eoi240030r14","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/jpi.2016.61.issue-3","article-title":"Melatonin as an antioxidant: under promises but over delivers.","volume":"61","author":"Reiter","year":"2016","journal-title":"J Pineal Res"},{"issue":"19","key":"eoi240030r15","doi-asserted-by":"publisher","first-page":"3934","DOI":"10.3390\/nu14193934","article-title":"Is melatonin the \u201cnext vitamin D\u201d?: a review of emerging science, clinical uses, safety, and dietary supplements.","volume":"14","author":"Minich","year":"2022","journal-title":"Nutrients"},{"key":"eoi240030r16","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.smrv.2016.06.005","article-title":"Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders.","volume":"34","author":"Auld","year":"2017","journal-title":"Sleep Med Rev"},{"issue":"11","key":"eoi240030r17","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1001\/archopht.120.11.1435","article-title":"The role of apoptosis in age-related macular degeneration.","volume":"120","author":"Dunaief","year":"2002","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"eoi240030r18","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13578-022-00879-3","article-title":"Melatonin inhibits NaIO3-induced ARPE-19 cell apoptosis via suppression of HIF-1a\/BNIP3-LC3B\/mitophagy signaling.","volume":"12","author":"Wang","year":"2022","journal-title":"Cell Biosci"},{"key":"eoi240030r19","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.727870","article-title":"Functions and diseases of the retinal pigment epithelium.","volume":"12","author":"Yang","year":"2021","journal-title":"Front Pharmacol"},{"key":"eoi240030r20","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/6819736","article-title":"Melatonin in retinal physiology and pathology: the case of age-related macular degeneration.","volume":"2016","author":"Blasiak","year":"2016","journal-title":"Oxid Med Cell Longev"},{"key":"eoi240030r21","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1196\/annals.1356.029","article-title":"Effects of melatonin in age-related macular degeneration.","volume":"1057","author":"Yi","year":"2005","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"eoi240030r22","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1017\/S0952523806230189","article-title":"Role of melatonin in the eye and ocular dysfunctions.","volume":"23","author":"Lundmark","year":"2006","journal-title":"Vis Neurosci"},{"key":"eoi240030r23","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.721869","article-title":"Therapeutic effects of melatonin on ocular diseases: knowledge map and perspective.","volume":"12","author":"Yu","year":"2021","journal-title":"Front Pharmacol"},{"issue":"1","key":"eoi240030r24","doi-asserted-by":"publisher","DOI":"10.1111\/jpi.2017.63.issue-1","article-title":"Melatonin: a pleiotropic molecule that modulates DNA damage response and repair pathways.","volume":"63","author":"Majidinia","year":"2017","journal-title":"J Pineal Res"},{"key":"eoi240030r25","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113556","article-title":"Melatonin: a window into the organ-protective effects of sepsis.","volume":"154","author":"Liu","year":"2022","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"eoi240030r26","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41419-022-04656-5","article-title":"Melatonin abolished proinflammatory factor expression and antagonized osteoarthritis progression in vivo.","volume":"13","author":"Liu","year":"2022","journal-title":"Cell Death Dis"},{"key":"eoi240030r27","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.888319","article-title":"Evidence for the benefits of melatonin in cardiovascular disease.","volume":"9","author":"Tobeiha","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"3","key":"eoi240030r28","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.ophtha.2005.12.013","article-title":"Prevalence of age-related macular degeneration in 4 racial\/ethnic groups in the multi-ethnic study of atherosclerosis.","volume":"113","author":"Klein","year":"2006","journal-title":"Ophthalmology"},{"issue":"4","key":"eoi240030r29","doi-asserted-by":"publisher","DOI":"10.1111\/jpi.v68.4","article-title":"Melatonin protects the retina from experimental nonexudative age-related macular degeneration in mice.","volume":"68","author":"Di\u00e9guez","year":"2020","journal-title":"J Pineal Res"},{"issue":"1","key":"eoi240030r30","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1134\/S2079057013040073","article-title":"Potential of melatonin for prevention of age-related macular degeneration: experimental study.","volume":"26","author":"Stefanova","year":"2013","journal-title":"Adv Gerontol"},{"issue":"1","key":"eoi240030r31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1210\/jcem-55-1-27","article-title":"Age-dependent reduction in serum melatonin concentrations in healthy human subjects.","volume":"55","author":"Iguichi","year":"1982","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"eoi240030r32","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1210\/jcem-66-3-648","article-title":"Alterations in nocturnal serum melatonin levels in humans with growth and aging.","volume":"66","author":"Waldhauser","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"eoi240030r33","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/jpi.1986.3.issue-4","article-title":"Human melatonin production decreases with age.","volume":"3","author":"Sack","year":"1986","journal-title":"J Pineal Res"},{"issue":"1","key":"eoi240030r35","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12933-016-0486-2","article-title":"Association of statin use and hypertriglyceridemia with diabetic macular edema in patients with type 2 diabetes and diabetic retinopathy.","volume":"16","author":"Chung","year":"2017","journal-title":"Cardiovasc Diabetol"},{"issue":"12","key":"eoi240030r36","doi-asserted-by":"publisher","first-page":"6494","DOI":"10.1074\/jbc.M115.687004","article-title":"Regulation of phagolysosomal digestion by caveolin-1 of the retinal pigment epithelium is essential for vision.","volume":"291","author":"Sethna","year":"2016","journal-title":"J Biol Chem"},{"issue":"1","key":"eoi240030r37","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1083\/jcb.33.1.61","article-title":"The renewal of photoreceptor cell outer segments.","volume":"33","author":"Young","year":"1967","journal-title":"J Cell Biol"},{"issue":"3","key":"eoi240030r38","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1152\/physrev.00021.2004","article-title":"The retinal pigment epithelium in visual function.","volume":"85","author":"Strauss","year":"2005","journal-title":"Physiol Rev"},{"issue":"7","key":"eoi240030r39","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.neurobiolaging.2005.05.012","article-title":"Mitochondrial alterations of retinal pigment epithelium in age-related macular degeneration.","volume":"27","author":"Feher","year":"2006","journal-title":"Neurobiol Aging"},{"issue":"4","key":"eoi240030r40","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.mam.2012.04.005","article-title":"Understanding age-related macular degeneration (AMD): relationships between the photoreceptor\/retinal pigment epithelium\/Bruch\u2019s membrane\/choriocapillaris complex.","volume":"33","author":"Bhutto","year":"2012","journal-title":"Mol Aspects Med"},{"issue":"5","key":"eoi240030r41","doi-asserted-by":"publisher","first-page":"799","DOI":"10.3390\/cells12050799","article-title":"Melatonin inhibits VEGF-induced endothelial progenitor cell angiogenesis in neovascular age-related macular degeneration.","volume":"12","author":"Lin","year":"2023","journal-title":"Cells"},{"issue":"4","key":"eoi240030r42","doi-asserted-by":"publisher","DOI":"10.1111\/jpi.2018.64.issue-4","article-title":"Melatonin attenuated retinal neovascularization and neuroglial dysfunction by inhibition of HIF-1a-VEGF pathway in oxygen-induced retinopathy mice.","volume":"64","author":"Xu","year":"2018","journal-title":"J Pineal Res"},{"key":"eoi240030r43","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/3528274","article-title":"Protective effects of melatonin on retinal inflammation and oxidative stress in experimental diabetic retinopathy.","volume":"2016","author":"Jiang","year":"2016","journal-title":"Oxid Med Cell Longev"},{"issue":"1","key":"eoi240030r44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1350-9462(02)00043-5","article-title":"Vascular endothelial growth factors and angiogenesis in eye disease.","volume":"22","author":"Witmer","year":"2003","journal-title":"Prog Retin Eye Res"},{"issue":"5","key":"eoi240030r45","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1093\/jamia\/ocac020","article-title":"Inaccuracies in electronic health records smoking data and a potential approach to address resulting underestimation in determining lung cancer screening eligibility.","volume":"29","author":"Kukhareva","year":"2022","journal-title":"J Am Med Inform Assoc"},{"issue":"52","key":"eoi240030r46","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000023818","article-title":"International Classification of Diseases, Tenth Revision, Clinical Modification social determinants of health codes are poorly used in electronic health records.","volume":"99","author":"Guo","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"eoi240030r47","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ijmedinf.2007.03.001","article-title":"An effort to improve electronic health record medication list accuracy between visits: patients\u2019 and physicians\u2019 response.","volume":"77","author":"Staroselsky","year":"2008","journal-title":"Int J Med Inform"},{"key":"eoi240030r48","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ajo.2017.05.016","article-title":"Physical activity and age-related macular degeneration: a systematic literature review and meta-analysis.","volume":"180","author":"McGuinness","year":"2017","journal-title":"Am J Ophthalmol"},{"issue":"14","key":"eoi240030r49","doi-asserted-by":"publisher","first-page":"6513","DOI":"10.1167\/iovs.17-23544","article-title":"Macular degeneration epidemiology: nature-nurture, lifestyle factors, genetic risk, and gene-environment interactions\u2014the Weisenfeld Award lecture.","volume":"58","author":"Seddon","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"eoi240030r50","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s40263-019-00680-w","article-title":"Adverse events associated with melatonin for the treatment of primary or secondary sleep disorders: a systematic review.","volume":"33","author":"Besag","year":"2019","journal-title":"CNS Drugs"},{"issue":"14","key":"eoi240030r52","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJM199704033361418","article-title":"Variable bioavailability of oral melatonin.","volume":"336","author":"Di","year":"1997","journal-title":"N Engl J Med"},{"issue":"7","key":"eoi240030r53","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1177\/00912700022009422","article-title":"The absolute bioavailability of oral melatonin.","volume":"40","author":"DeMuro","year":"2000","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"eoi240030r54","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/1099-081X(200001)21:1<15::AID-BDD215>3.0.CO;2-H","article-title":"Bioavailability of melatonin in humans after day-time administration of D(7) melatonin.","volume":"21","author":"Fourtillan","year":"2000","journal-title":"Biopharm Drug Dispos"},{"key":"eoi240030r1","unstructured":"Blindness and vision impairment. World Health Organization. 2023. Accessed January 25, 2024. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/blindness-and-visual-impairment"},{"key":"eoi240030r9","unstructured":"SYFOVRETM (pegcetacoplan injection), for intravitreal use. Prescribing information. US Food and Drug Administration; 2023. Accessed December 26, 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/217171s000lbl.pdf"},{"key":"eoi240030r10","unstructured":"IZERVAYTM (avacincaptad pegol intravitreal solution). Prescribing information. US Food and Drug Administration; 2023. Accessed December 26, 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/217225s000lbl.pdf"},{"key":"eoi240030r34","unstructured":"Prevalence of age-related macular degeneration (AMD). Centers for Disease Control and Prevention. May 2, 2023. Accessed June 17, 2023. https:\/\/www.cdc.gov\/visionhealth\/vehss\/estimates\/amd-prevalence.html"},{"key":"eoi240030r51","unstructured":"Dietary Supplement Health and Education Act of 1994. National Institutes of Health: Office of Dietary Supplements; 1994. Accessed January 5, 2024. https:\/\/ods.od.nih.gov\/About\/DSHEA_Wording.aspx"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2819801\/jamaophthalmology_jeong_2024_oi_240030_1719935949.45527.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T15:04:00Z","timestamp":1721315040000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2819801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":54,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2024.1822","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,1]]}}}